Terms: = Ovarian cancer AND BTK, AGMX1, 695, ENSG00000010671, XLA, IMD1, RP1-164F3_2, MGC126262, BPK, ATK, MGC126261, Q06187, AT, PSCTK1
39754 results:
1. Current data and future perspectives on DNA methylation in ovarian cancer (Review).
Fu M; Deng F; Chen J; Fu L; Lei J; Xu T; Chen Y; Zhou J; Gao Q; Ding H
Int J Oncol; 2024 Jun; 64(6):. PubMed ID: 38757340
[TBL] [Abstract] [Full Text] [Related]
2. Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer.
Li H; Peng Z; Zhu J; Zhao W; Huang Y; An R; Zheng H; Qu P; Wang L; Zhou Q; Wang D; Lou G; Wang J; Wang K; Kong B; Xie X; Yin R; Low J; Rozita AM; Sen LC; Meng YC; Kiong KS; Liu J; Liang Z; Lv W; Zhu Y; Hu W; Sun W; Su J; Wang Q; Zang R; Ma D; Gao Q
BMC Med; 2024 May; 22(1):199. PubMed ID: 38755585
[TBL] [Abstract] [Full Text] [Related]
3. When to reinvite initially ineligible populations for targeted lung cancer screening?
Goodley P; Crosbie PAJ; Sperrin M; Merchant Z; Booton R; Balata H
BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38754907
[TBL] [Abstract] [Full Text] [Related]
4. Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant ovarian cancer: Findings From Cohort A of the OPAL Phase II Trial.
Liu JF; Gaillard S; Wahner Hendrickson AE; Yeku O; Diver E; Gunderson Jackson C; Arend R; Ratner E; Samnotra V; Gupta D; Chung J; Zhang H; Compton N; Baines A; Bacqué E; Liu X; Felicetti B; Konecny GE
JCO Precis Oncol; 2024 May; 8():e2300693. PubMed ID: 38754056
[TBL] [Abstract] [Full Text] [Related]
5. Feasibility and cost-effectiveness of genetic counselling for all patients with newly diagnosed ovarian cancer: a single-centre retrospective study.
Schlootz S; Saner FAM; Rabaglio M; Imboden S; Wampfler J
Swiss Med Wkly; 2024 Apr; 154():3386. PubMed ID: 38754016
[TBL] [Abstract] [Full Text] [Related]
6. Small Nucleolar RNAs as Diagnostic and Prognostic Biomarkers in cancer: A Systematic Review and Meta-Analysis.
Gao L; Fan J; He J; Che X; Wang X; Han C
Technol Cancer Res Treat; 2024; 23():15330338241245939. PubMed ID: 38752263
[TBL] [Abstract] [Full Text] [Related]
7. Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors.
Chung DC; Ghaedi M; Warner K; Sayad A; Saibil SD; Bernardini MQ; Clarke BA; Shaw PA; Butler MO; Easson A; Morrissy S; Wang BX; Nguyen L; Ohashi PS; Jacquelot N
Oncoimmunology; 2024; 13(1):2349347. PubMed ID: 38746870
[TBL] [Abstract] [Full Text] [Related]
8. Transcript and protein signatures derived from shared molecular interactions across cancers are associated with mortality.
Zhao Y; Li X; Loscalzo J; Smelik M; Sysoev O; Wang Y; Mahmud AKMF; Mansour Aly D; Benson M
J Transl Med; 2024 May; 22(1):444. PubMed ID: 38734658
[TBL] [Abstract] [Full Text] [Related]
9. Blood Lead Level as Marker of Increased Risk of ovarian cancer in BRCA1 Carriers.
Kiljańczyk A; Matuszczak M; Marciniak W; Derkacz R; Stempa K; Baszuk P; Bryśkiewicz M; Lubiński K; Cybulski C; Dębniak T; Gronwald J; Huzarski T; Lener MR; Jakubowska A; Szwiec M; Stawicka-Niełacna M; Godlewski D; Prusaczyk A; Jasiewicz A; Kluz T; Tomiczek-Szwiec J; Kilar-Kobierzycka E; Siołek M; Wiśniowski R; Posmyk R; Jarkiewicz-Tretyn J; Sun P; Scott RJ; Narod SA; Lubiński J
Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732616
[TBL] [Abstract] [Full Text] [Related]
10. The Role of Glutathione Transferase Omega-Class Variant Alleles in Individual Susceptibility to ovarian cancer.
Simic P; Coric V; Pljesa I; Savic-Radojevic A; Zecevic N; Kocic J; Simic T; Pazin V; Pljesa-Ercegovac M
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732205
[TBL] [Abstract] [Full Text] [Related]
11. Racial and Ethnic Disparities in the Incidence of Anti-NMDA Receptor Encephalitis.
Alsalek S; Schwarzmann KB; Budhathoki S; Hernandez-Lopez V; Smith JB; Li BH; Langer-Gould A
Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200255. PubMed ID: 38728608
[TBL] [Abstract] [Full Text] [Related]
12. Fertility-sparing surgery in children and adolescents with borderline ovarian tumors: a retrospective study.
Zhao J; Wang D; Wang R; He Y; Jia C; Pan L; Ma S; Wu M; Wang W; Cheng X; Yang J; Xiang Y
J Ovarian Res; 2024 May; 17(1):96. PubMed ID: 38720349
[TBL] [Abstract] [Full Text] [Related]
13. Risk of Subsequent Primary cancers Among Adult-Onset 5-Year cancer Survivors in South Korea: Retrospective Cohort Study.
Choi YY; Lee M; Kim EH; Lee JE; Jung I; Cheong JH
JMIR Public Health Surveill; 2024 May; 10():e48380. PubMed ID: 38717807
[TBL] [Abstract] [Full Text] [Related]
14. [Study of antitumor effects of human placenta hydrolysate on PC-3, OAW-42, BT-474 cell cultures].
Gromova OA; Filimonova MV; Torshin IY; Frolova DЕ
Ter Arkh; 2024 Apr; 96(3):266-272. PubMed ID: 38713042
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic factors and the role of primary debulking in operable stage IVB ovarian cancer with supraclavicular lymph node metastasis: a retrospective study in Chinese patients.
Quan C; Chen X; Wen H; Wu X; Li J
BMC Cancer; 2024 May; 24(1):565. PubMed ID: 38711015
[TBL] [Abstract] [Full Text] [Related]
16. piR-1919609 Is an Ideal Potential Target for Reversing Platinum Resistance in ovarian cancer.
Yan Y; Tian D; Zhao B; Li Z; Huang Z; Li K; Chen X; Zhou L; Feng Y; Yang Z
Technol Cancer Res Treat; 2024; 23():15330338241249692. PubMed ID: 38706262
[TBL] [Abstract] [Full Text] [Related]
17. NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cells.
Liu C; Vorderbruggen M; Muñoz-Trujillo C; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS; Karpf AR
J Ovarian Res; 2024 May; 17(1):94. PubMed ID: 38704607
[TBL] [Abstract] [Full Text] [Related]
18. Perioperative management of a patient with unexpectedly detected early-stage ovarian mucinous carcinoma combined with progressive bulbar paralysis: a case report and literature review.
Zhang D; Xu R; Huo T; Liu Y; Hao Z; Sun Y; Xi X; Du X; Wang L; Du J
BMC Womens Health; 2024 May; 24(1):274. PubMed ID: 38704534
[TBL] [Abstract] [Full Text] [Related]
19. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.
Belotte J; Felicetti B; Baines AJ; YoussefAgha A; Rojas-Espaillat L; Ortiz AG; Provencher D; Vázquez RM; Cortijo LG; Zeng X
Trials; 2024 May; 25(1):301. PubMed ID: 38702828
[TBL] [Abstract] [Full Text] [Related]
20. Predictors of Blood Transfusion in Patients Undergoing Cytoreductive Surgeries for ovarian Malignancy.
Pearce JV; Zhao J; Randall L; Sullivan SA; Miller D; Tossas K
South Med J; 2024 May; 117(5):266-271. PubMed ID: 38701848
[TBL] [Abstract] [Full Text] [Related]
[Next]
